- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05661682
Tralement Versus a Fixed-dose Trace Element Combination Product of Zinc, Copper, and Selenious Acid to Evaluate Product Safety in Adult Patients Requiring Long-term Parenteral Nutrition
A Randomized, Single-blind, Trial of Tralement Versus a Fixed-dose Trace Element Combination Product of Zinc, Copper, and Selenious Acid to Evaluate Manganese Safety in Adult Patients Requiring Long-term Parenteral Nutrition
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A Phase IV, multi-center, randomized single-blind trial to evaluate the safety profile of Tralement versus a fixed-dose trace element product of zinc, copper, and selenious acid in adult patients who are expected to require at least six-months of home parenteral nutrition.
This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of parenteral nutrition requiring trace element additives. Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.
Eligible participants who satisfy the inclusion requirements and no exclusion criteria will be consented to participate in this study and enter the screening study phase.
The screening evaluation will be conducted within 5 days of the dose administration of study drug. Study participants meeting entry criteria of normal brain MRI and laboratory manganese concentrations (whole blood/plasma/serum/RBC) will begin study drug on Day 1.
Participants will undergo 2 additional post-baseline brain MRI scans at Months 3 and 6 and have 5 separate neuropsychological tests at Day 1, Month 3, and Month 6. Additional clinical monitoring including safety and laboratory assessments will occur during the 6-month opt-in extension study.
All patients in each assigned trace element parenteral nutrition group will have parenteral nutrition formulations evaluated for manganese content at Day 1, Month 1, Month 3, and Month 6.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Mark Falone, MD
- Phone Number: 6318168908
- Email: mfalone@americanregent.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult (≥18 to ≤80 years of age) participants able to provide informed consent.
- Male and female participants who are new users to home parenteral nutrition as a source of trace elements when oral or enteral nutrition is not possible, insufficient, or, contraindicated.
- Anticipated duration of home parenteral nutrition use is 6 months or greater.
- A normal baseline brain MRI scan.
- A normal blood manganese concentration.
- Ability to undergo additional 2 brain MRI scans over the six-month study period (Sedation, if appropriate, to be determined by the Principal Investigator's study site, institutional review board recommendations).
- Definitive contraception for females of reproductive age.
Exclusion Criteria:
- Prior parenteral nutrition therapy.
- Hypersensitivity or allergy to zinc or copper.
- History of occupational exposure to manganese and documented by laboratory test results.
- Baseline ferritin ≥300 ng/mL or below 100 ng/mL.
- Baseline transferrin saturation (TSAT) ≥45 % or below 20%.
- Prior or current cholestatic liver disease defined as a clinical condition associated with decrease in bile flow due to impaired secretion by hepatocytes or to obstruction of bile flow through intra-or extrahepatic bile ducts.
- Liver function studies with transaminases greater than two-fold normal or total bilirubin >2 mg/dL.
- Brain MRI exclusion criteria: MRI-unsafe metal implants, claustrophobia.
- Known excess environmental exposure to manganese.
- Less than 1-year expected survival, as anticipated by their primary provider.
- Current participation in another clinical trial.
- Females in pregnant state.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Tralement
This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of parenteral nutrition formulation requiring trace element additives.
Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.
|
Tralement with Manganese Sulfate
Other Names:
|
Active Comparator: a fixed-dose trace element combination product of zinc sulfate, copper sulfate, and selenious acid
This study will enroll new prescribed home parenteral nutrition users, i.e. a patient enrolled in the study within six weeks of initiating first-time use of parenteral nutrition formulation requiring trace element additives.
Note: a portion of patients who meet inclusion criteria may have received parenteral nutrition in an inpatient setting before discharge home.
|
Tralement without Manganese Sulfate
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess brain deposition of manganese in Tralement versus a fixed-dose trace element product of zinc, copper, and selenious acid.
Time Frame: 6 Months
|
Change from baseline in basal ganglia index (BG-index) as determined by T1-weighted brain MRI images.
|
6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the efficacy & safety of Tralement versus a fixed-dose trace element product of zinc, copper, and selenious acid.
Time Frame: 6 Months
|
Change from baseline in blood (plasma/serum/RBC) manganese levels assessed
|
6 Months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TE20001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Manganese Safety in Adults
-
American Regent, Inc.Not yet recruiting
-
Assiut UniversityRecruitingVocal Nodules in AdultsEgypt
-
Beckley Psytech LimitedCompletedPharmacokinetics in Healthy AdultsUnited Kingdom
-
Orion Corporation, Orion PharmaCompletedContinuous Sedation in Initially Sedated Adults in ICUFinland, United Kingdom, Belgium, Germany, Netherlands, Russian Federation, Switzerland
-
Orion Corporation, Orion PharmaCompletedContinuous Sedation in Initially Sedated Adults in ICUNetherlands, Belgium, Estonia, Finland, France, Germany, Norway, Switzerland, United Kingdom
-
Beckley Psytech LimitedCompletedPharmacokinetics in Healthy AdultsUnited Kingdom
-
scPharmaceuticals, Inc.CompletedPharmacokinetics in Healthy Adults
-
University of Alabama at BirminghamCompletedPhysical Fitness in Older AdultsUnited States
-
University of ZurichCompletedMotivation in Healthy Older AdultsSwitzerland
-
Stony Brook UniversityMartinos Center for Biomedical ImagingCompleted
Clinical Trials on Tralement
-
American Regent, Inc.Not yet recruiting